MX2013010392A - Proteinas de fusion npp1. - Google Patents

Proteinas de fusion npp1.

Info

Publication number
MX2013010392A
MX2013010392A MX2013010392A MX2013010392A MX2013010392A MX 2013010392 A MX2013010392 A MX 2013010392A MX 2013010392 A MX2013010392 A MX 2013010392A MX 2013010392 A MX2013010392 A MX 2013010392A MX 2013010392 A MX2013010392 A MX 2013010392A
Authority
MX
Mexico
Prior art keywords
fusion polypeptide
fusion proteins
vector
npp1
npp1 fusion
Prior art date
Application number
MX2013010392A
Other languages
English (en)
Other versions
MX361434B (es
Inventor
Anthony Quinn
Alex J Harvey
Zhinan Xia
Original Assignee
Synageva Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/028233 external-priority patent/WO2011113027A2/en
Application filed by Synageva Biopharma Corp filed Critical Synageva Biopharma Corp
Publication of MX2013010392A publication Critical patent/MX2013010392A/es
Publication of MX361434B publication Critical patent/MX361434B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

La presente invención proporciona un polipéptido de fusión novedoso que contiene un dominio catalítico de NPP1 fusionado a un resto de direccionamiento, ácidos nucleicos que codifican el polipéptido de fusión, un vector que contiene el ácido nucleico integrado en este, una célula hospedadora transformada con el vector y composiciones farmacéuticas que comprenden el polipéptido de fusión.
MX2013010392A 2011-03-11 2011-09-15 Proteínas de fusión npp1. MX361434B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2011/028233 WO2011113027A2 (en) 2010-03-12 2011-03-11 Npp1 fusion proteins
PCT/US2011/051858 WO2012125182A1 (en) 2011-03-11 2011-09-15 Npp1 fusion proteins

Publications (2)

Publication Number Publication Date
MX2013010392A true MX2013010392A (es) 2014-03-27
MX361434B MX361434B (es) 2018-12-06

Family

ID=46831271

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010392A MX361434B (es) 2011-03-11 2011-09-15 Proteínas de fusión npp1.

Country Status (9)

Country Link
EP (1) EP2683742B1 (es)
KR (1) KR101772366B1 (es)
CN (1) CN103443128B (es)
AU (1) AU2011362576B2 (es)
CA (1) CA2829767C (es)
MX (1) MX361434B (es)
RU (1) RU2601154C2 (es)
SG (1) SG193024A1 (es)
WO (1) WO2012125182A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014126965A2 (en) * 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
EP3234116B1 (en) 2014-12-19 2021-09-08 Alexion Pharmaceuticals, Inc. Methods of treating tissue calcification
US10787523B2 (en) * 2015-01-29 2020-09-29 University Of Massachusetts Nanoparticle-protein complex for intracellular protein delivery
JP6995627B2 (ja) * 2015-05-19 2022-02-04 イエール ユニバーシティ 病的石灰化状態を治療するための組成物およびそれを使用する方法
WO2017218786A1 (en) 2016-06-16 2017-12-21 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
US11390859B2 (en) 2016-08-05 2022-07-19 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
US20220119782A1 (en) * 2018-08-31 2022-04-21 Yale University ENPP1 Polypeptides and Methods of Using Same
CA3181983A1 (en) 2020-06-09 2021-12-16 Zhiliang Cheng Soluble enpp1 or enpp3 proteins and uses thereof
CN113388625B (zh) * 2021-06-03 2022-06-24 广西大学 一种甘蔗梢腐病效应因子Fs_00548基因及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US6825396B2 (en) 1996-06-12 2004-11-30 Board Of Trustees Operating Michigan State University Methods for tissue specific synthesis of protein in eggs of transgenic hens
KR20010031190A (ko) 1997-10-16 2001-04-16 아비게닉스, 인코포레이티드 조류 트랜스제네시스용 매그넘-특이적 프로모터를함유하는 벡터
US20040019923A1 (en) 1997-10-16 2004-01-29 Ivarie Robert D. Exogenous proteins expressed in avians and their eggs
US5932465A (en) * 1997-10-16 1999-08-03 Icos Corporation Phosphodiesterase 8A
AU748587B2 (en) 1997-11-07 2002-06-06 Trillium Therapeutics Inc Methods and compositions for immunomodulation
DE20121960U1 (de) * 2000-04-06 2004-01-15 Epigenomics Ag Nukleinsäuren für die Diagnose von mit Metastase assoziierten Krankheiten
US20020108132A1 (en) 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
US7323542B2 (en) 2002-02-21 2008-01-29 University Of Virginia Patent Foundation Bone targeting peptides
US20050090001A1 (en) 2003-10-07 2005-04-28 Parker Stephen H. Cell lines and methods for producing proteins
ES2628841T3 (es) * 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1

Also Published As

Publication number Publication date
AU2011362576A1 (en) 2013-09-19
EP2683742A4 (en) 2014-08-06
CA2829767C (en) 2023-08-29
MX361434B (es) 2018-12-06
RU2013142583A (ru) 2015-04-20
CN103443128B (zh) 2017-11-24
KR101772366B1 (ko) 2017-08-28
EP2683742A1 (en) 2014-01-15
EP2683742B1 (en) 2018-12-19
SG193024A1 (en) 2013-10-30
WO2012125182A1 (en) 2012-09-20
AU2011362576B2 (en) 2017-06-08
CN103443128A (zh) 2013-12-11
CA2829767A1 (en) 2012-09-20
RU2601154C2 (ru) 2016-10-27
KR20170018473A (ko) 2017-02-17

Similar Documents

Publication Publication Date Title
MX361434B (es) Proteínas de fusión npp1.
WO2011113027A3 (en) Npp1 fusion proteins
BR112014019901A8 (pt) Proteínas de fator viii recombinante
MY162737A (en) 4-1bb binding molecules
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
PH12014501360A1 (en) Compositions and methods for modifying a predetermined target nucleic acid sequence
IN2014CN04586A (es)
CL2013001124A1 (es) Anticuerpo aislado o una proteína que comprende una porción de enlace de antígeno de un anticuerpo dirigido contra un polipéptido de cd40; composicion farmacéutica que comprende dicho anticuerpo; ácido nucleico que codifica el anticuerpo; vector de clonación; proceso de producción del anticuerpo.
IN2014CN00650A (es)
IN2014CN00597A (es)
GB201008682D0 (en) Epitope tag for affinity based applications
MX2014004598A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2014004539A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2018015914A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina.
TN2014000360A1 (en) Cx3cr1-binding polypeptides
WO2013119302A3 (en) Gh61 polypeptide variants and polynucleotides encoding same
MX2013003236A (es) Variantes de polipeptidos que tienen actividad potenciadora celulolitica y polinucleotidos que codifican a los mismos.
MX2013003237A (es) Variantes de polipeptidos que tienen actividad potenciadora celulolitica y polinucleotidos que codifican a los mismos.
EP2576626A4 (en) FUNCTIONAL AND STABLE CLASS I CELLOBIOHYDROLASTIC ENZYMES
MX358963B (es) Polipeptidos con actividad proteasa.
MX349517B (es) Polipeptidos que tienen actividad de proteasa y polinucleotidos que codifican los mismos.
AR092879A1 (es) Proteinas de fusion de g3p como agentes de union a amiloide
NZ713602A (en) Method for refining protein including self-cutting cassette and use thereof
MX2016012840A (es) Moléculas para transporte de antígeno modular mejoradas y sus usos.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: ALEXION PHARMACEUTICALS, INC.